Literature DB >> 18042732

2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.

Earl Gordon1, Irina M Lozinskaya, Zuojun Lin, Simon F Semus, Frank E Blaney, Robert N Willette, Xiaoping Xu.   

Abstract

Long and short QT syndromes associated with loss and gain of human ether-a-go-go-related gene (hERG) channel activity, respectively, can cause life-threatening arrhythmias. As such, modulation of hERG channel activity is an important consideration in the development of all new therapeutic agents. In the present study, we investigated the mechanisms of action of 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243), a known hERG channel activator, on hERG channels stably expressed in Chinese hamster ovary (CHO) cells using the patch-clamp technique. In the whole-cell recordings, the extracellular application of PD-307243 concentration-dependently increased the hERG current and markedly slowed hERG channel deactivation and inactivation. PD-307243 had no effect on the selectivity filter of hERG channels. The activity of PD-307243 was use-dependent. PD-307243 (3 and 10 muM) induced instantaneous hERG current with little decay at membrane potentials from -120 to -40 mV. At more positive voltages, PD-307243 induced an I(to)-like upstroke of hERG current. The actions of PD-307243 on the rapid component of delayed rectifier K(+) current (I(Kr)) in rabbit ventricular myocytes were similar to those observed in hERG channel-transfected CHO cells. Inside-out patch experiments revealed that PD-307243 increased hERG tail currents by 2.1 +/- 0.6 (n = 7) and 3.4 +/- 0.3-fold (n = 4) at 3 and 10 muM, respectively, by slowing the channel deactivation but had no effect on channel activation. During a voltage-clamp protocol using a prerecorded cardiac action potential, 3 muM PD-307243 increased the total potassium ions passed through hERG channels by 8.8 +/- 1.0-fold (n = 5). Docking studies suggest that PD-307243 interacts with residues in the S5-P region of the channel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042732     DOI: 10.1124/mol.107.041152

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

Review 3.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

4.  Modulation of Kv 11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator.

Authors:  Harinath Sale; Samrat Roy; Jayakumar Warrier; Srinivasan Thangathirupathy; Yoganand Vadari; Shruthi K Gopal; Prasad Krishnamurthy; Manjunath Ramarao
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

Review 5.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.

Authors:  Ping-zheng Zhou; Joseph Babcock; Lian-qing Liu; Min Li; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2011-05-30       Impact factor: 6.150

6.  A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels.

Authors:  Marcus Schewe; Han Sun; Ümit Mert; Alexandra Mackenzie; Ashley C W Pike; Friederike Schulz; Cristina Constantin; Kirsty S Vowinkel; Linus J Conrad; Aytug K Kiper; Wendy Gonzalez; Marianne Musinszki; Marie Tegtmeier; David C Pryde; Hassane Belabed; Marc Nazare; Bert L de Groot; Niels Decher; Bernd Fakler; Elisabeth P Carpenter; Stephen J Tucker; Thomas Baukrowitz
Journal:  Science       Date:  2019-02-22       Impact factor: 47.728

7.  A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome.

Authors:  Kirstine Calloe; Jonathan M Cordeiro; José M Di Diego; Rie S Hansen; Morten Grunnet; Søren Peter Olesen; Charles Antzelevitch
Journal:  Cardiovasc Res       Date:  2008-12-10       Impact factor: 10.787

8.  A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.

Authors:  Matthew Perry; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2007-12-27       Impact factor: 4.436

Review 9.  HERG1 channel agonists and cardiac arrhythmia.

Authors:  Michael C Sanguinetti
Journal:  Curr Opin Pharmacol       Date:  2013-11-27       Impact factor: 5.547

10.  Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243).

Authors:  Xulin Xu; Maurizio Recanatini; Marinella Roberti; Gea-Ny Tseng
Journal:  Mol Pharmacol       Date:  2008-03-27       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.